Physician profile
Jayati Rakhit
NPI 1174511505
$800.33
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $351 · 2020: $148 · 2021: $188 · 2022: $114.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $175.70 | 2019-2022 | |
| Novo Nordisk INC | $149.75 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $124.35 | 2019-2022 | |
| Amarin Pharma, INC. | $62.57 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $62.50 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $55.55 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.19 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $34.21 | 2022 | |
| Abbott Laboratories | $20.81 | 2019 | |
| Bardy Diagnostics, INC. | $18.00 | 2021 | |
| Janssen Pharmaceuticals, INC | $17.22 | 2019 | |
| Boston Scientific Corporation | $16.93 | 2020 | |
| Portola Pharmaceuticals, LLC | $13.27 | 2019 | |
| Esperion Therapeutics, INC. | $11.28 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jayati Rakhit listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.